MUMO-1 is under clinical development by Esteve Pharmaceuticals and currently in Phase I for Unspecified Pain. According to GlobalData, Phase I drugs for Unspecified Pain does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the MUMO-1 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MUMO-1 overview
MUMO-1 is under development for the treatment of pain related diseases. The drug candidate acts by targeting the sigma-1 receptor. It is developed based on multi-modal (MuMo) technology platform. The drug candidate is a new chemical entity (NCE).
Esteve Pharmaceuticals overview
Esteve Pharmaceuticals (Esteve) researches, develops, and markets prescription and generic pharmaceuticals. The company’s product portfolio includes prescription drugs, over the counter (OTC) pharmaceuticals, and generic drugs. It offers drugs for the central nervous system, infection, respiratory, cardiovascular, cancer, primary care, and other therapeutic areas. Esteve also provides customized contract manufacturing services of active pharmaceutical ingredients (APIs) and advanced intermediates for the global pharmaceutical industry. The company markets its products to pharmaceutical companies, healthcare facilities and other customers through licensing agreements and distributors. It operates subsidiaries and production centers in Europe, the Americas, Africa, Oceania, and Asia. Esteve is headquartered in Barcelona, Spain.
For a complete picture of MUMO-1’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
